LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Allogene Therapeutics Inc

Fechado

SetorSaúde

1.17 -0.85

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.16

Máximo

1.19

Indicadores-chave

By Trading Economics

Rendimento

206K

-60M

EPS

-0.28

Margem de lucro

272,450

Funcionários

226

EBITDA

-302K

-56M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+611.97% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-24M

232M

Abertura anterior

2.02

Fecho anterior

1.17

Sentimento de Notícias

By Acuity

76%

24%

355 / 381 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Allogene Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mai. de 2025, 10:30 UTC

Principais Notícias

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 de mai. de 2025, 06:30 UTC

Ganhos

5 Things We've Learned From Retail Earnings -- Barrons.com

31 de mai. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

30 de mai. de 2025, 23:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 de mai. de 2025, 21:30 UTC

Principais Notícias

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 de mai. de 2025, 21:15 UTC

Principais Notícias

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 de mai. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

30 de mai. de 2025, 20:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 de mai. de 2025, 20:24 UTC

Principais Notícias

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 de mai. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

30 de mai. de 2025, 19:44 UTC

Conversa de Mercado

Gold Breaks 4-Month Winning Streak -- Market Talk

30 de mai. de 2025, 19:38 UTC

Conversa de Mercado

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 de mai. de 2025, 19:29 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 de mai. de 2025, 19:14 UTC

Conversa de Mercado

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 de mai. de 2025, 19:05 UTC

Conversa de Mercado

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 de mai. de 2025, 18:51 UTC

Conversa de Mercado

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 de mai. de 2025, 18:37 UTC

Conversa de Mercado
Ganhos

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 de mai. de 2025, 18:04 UTC

Principais Notícias

S&P 500 Falls After More Trump-China Friction -- WSJ

30 de mai. de 2025, 17:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de mai. de 2025, 17:47 UTC

Conversa de Mercado

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 de mai. de 2025, 17:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 de mai. de 2025, 17:38 UTC

Conversa de Mercado

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 de mai. de 2025, 17:31 UTC

Conversa de Mercado

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 de mai. de 2025, 17:14 UTC

Principais Notícias

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 de mai. de 2025, 16:31 UTC

Ganhos

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 de mai. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

30 de mai. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

30 de mai. de 2025, 16:16 UTC

Principais Notícias

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 de mai. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

30 de mai. de 2025, 16:14 UTC

Principais Notícias

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Comparação entre Pares

Variação de preço

Allogene Therapeutics Inc Previsão

Preço-alvo

By TipRanks

611.97% parte superior

Previsão para 12 meses

Média 8.33 USD  611.97%

Máximo 14 USD

Mínimo 4 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Allogene Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

10

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.18 / 1.69Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

355 / 381 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.